Ana M. Aparicio

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

  JAMA Oncology · 2023 · 10.1001/jamaoncol.2023.0161

• Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

  European Journal of Cancer · 2023 · 10.1016/j.ejca.2023.02.018

• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

  European Urology · 2022 · 10.1016/j.eururo.2022.11.002

• Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

  Science Translational Medicine · 2020 · 10.1126/scitranslmed.aaz3577

• Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

  Cell · 2019 · 10.1016/j.cell.2019.10.029

• Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30408-5

• Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

  Journal of Clinical Investigation · 2018 · 10.1172/jci99760

• Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

  Science Signaling · 2017 · 10.1126/scisignal.aam7479

• Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

  Proceedings of the National Academy of Sciences · 2016 · 10.1073/pnas.1611421113

• Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions

  Current Medicinal Chemistry · 2016 · 10.2174/0929867323666161214114948

• Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

  Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-15-1259

• Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer

  European Urology · 2014 · 10.1016/j.eururo.2014.05.005

• Aggressive Variants of Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-13-3309

• Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer

  Cancer Discovery · 2013 · 10.1158/2159-8290.cd-12-0460

• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-12-3791

• A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma

  European Urology · 2012 · 10.1016/j.eururo.2012.06.043

• Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes

  Cancer Discovery · 2011 · 10.1158/2159-8290.cd-11-0259

• Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-1867

• Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.3660

• A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-08-0122

• Epigenetics in human disease and prospects for epigenetic therapy

  Nature · 2004 · https://doi.org/10.1038/nature02625

• Neoplastic meningitis

  Current Neurology and Neuroscience Reports · 2002 · 10.1007/s11910-002-0081-7

• In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

  Leukemia · 1998 · 10.1038/sj.leu.2400892

• The Yeast Genome Directory

  Nature · 1997 · 10.1038/387s005

Current projects

No projects listed.